ICER and NEWDIGS Release White Paper Analyzing the Challenges and Potential Policy Options for Paying for Gene Therapies: icer.org/news-insights/…

ICER #WeeklyView : an upcoming gene therapy paper, ICER @ AMCP 2024, & CVS Health covers Humira biosimilars conta.cc/49ID6nB

ICER’s President and CEO Sarah Emond spoke at #AMCP2024 in New Orleans yesterday. She described ICER’s approach to #patientengagement .

Many thanks to AMCP for hosting this event and inviting ICER to attend! #heor #hta

All set up to record the AMCP Podcast Series - Listen Up at the ⁦AMCP⁩ annual conference to be aired on ⁦HealthcareNOWradio⁩. Stay tuned for episodes w/ ⁦⁦Sarah Emond⁩ ICER⁩ & topics on legislation, Format 5.0, #weareMCPs & more #amcp2024 #pharmacy

Tomorrow, ICER’s President and CEO
Sarah Emond will be speaking at #AMCP2024 . She’ll discuss several topics, including ICER’s approach to patient engagement.

Learn more: amcpannual.org

This year at #AHIP2024 , ICER's Chief Medical Officer David Rind will be sharing insights on the obesity management space along with other industry experts.

Learn more: hubs.li/Q02ldnCs0

🎉🏥 Don't miss out on the In the Trenches Seminars at HCP! Featuring special guests Dr. Thomas Lee of Galileo on April 18th, and Dr. David Rind from ICER on May 8th! 🩺David Rind ICER Harvard Medical School

ICER #WeeklyView : COPD Draft Report, UPI Protocol, & VA vetoes a PDAB conta.cc/4aUhi9N

ICER’s President & CEO Sarah Emond and ICER’s CSO & Director of HTA Methods and Engagement Dan Ollendorf attended the CEVR Annual Meeting yesterday. They discussed updates to the ICER Value Assessment Framework, the cell and gene therapy landscape, and other HTA/HEOR topics

ICER Releases Draft Evidence Report on Treatment for Chronic Obstructive Pulmonary Disease: icer.org/pressreleases/…

ICER Publishes 2024 Research Protocol for Assessing Unsupported Price Increases on Prescription Drugs: icer.org/news-insights/…

ICER #WeeklyView : Relyvrio's removal, State Medicaid discussions for Lenmeldy, & IRA Rx pricing negotiations continue conta.cc/3TOS6uo

On April 16th, ICER’s President and CEO Sarah Emond will be speaking at AMCP 2024.

She’ll discuss several topics, including ICER’s approach to patient engagement. Learn more: amcpannual.org

ICER #WeeklyView : Approvals for Rezdiffra, Lenmeldy, Winrevair, and ICER's PTSD Draft Report conta.cc/3TGhxy2

On April 2nd, ICER is hosting an 'Early Insights' webinar with our Chief Medical Officer, David Rind, to explain ICER's #PTSD Draft Report on MDMA-AP.

This webinar is available to all users of the ICER Analytics platform: us02web.zoom.us/webinar/regist…

ICER Releases Draft Evidence Report on Treatment for Post-Traumatic Stress Disorder: icer.org/news-insights/…

Excited to share the framework for our ICER developed Clinical trial Diversity Rating (CDR) tool. Our tool systematically measures clinical trial diversity based on prevalence data. We encourage groups to use our framework to monitor and improve diversity in trials!

ICER #WeeklyView : A new ICER Governance Board member & Final Reports for schizophrenia and PNH
conta.cc/3TzIX9V

(ICER is issuing the Weekly View a day early this week due to some scheduling constraints. And, the next Weekly View will be in your inbox on March 29th.)

Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatments for Paroxysmal Nocturnal Hemoglobinuria:
icer.org/news-insights/…

Tomorrow, ICER's Dan Ollendorf will be part of a panel at AHIP’s Medicare, Medicaid, Duals & Commercial Markets Forum on 'Trends in Prescription Drug Affordability, Innovation and Access.'

Join the discussion at #GovMktsForum !